ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.
ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.
复制标题
SARS-CoV-2 (AIDS)肽ace -2相互作用结构域抑制小鼠炎症以退热并保护肺和心脏:对COVID-19治疗的影响
DOI:
10.1007/s11481-020-09979-8
复制
发表时间:
2021-03
期刊:
影响因子:
--
通讯作者:
Pahan K
中科院分区:
文献类型:
--
作者:
Paidi RK;Jana M;Mishra RK;Dutta D;Raha S;Pahan K
COVID-19 is an infectious respiratory illness caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and until now, there is no effective therapy against COVID-19. Since SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) for entering into host cells, to target COVID-19 from therapeutic angle, we engineered a hexapeptide corresponding to the ACE2-interacting domain of SARS-CoV-2 (AIDS) that inhibits the association between receptor-binding domain-containing spike S1 and ACE-2. Accordingly, wild type (wt), but not mutated (m), AIDS peptide inhibited SARS-CoV-2 spike S1-induced activation of NF-κB and expression of IL-6 in human lungs cells. Interestingly, intranasal intoxication of C57/BL6 mice with recombinant SARS-CoV-2 spike S1 led to fever, increase in IL-6 in lungs, infiltration of neutrophils into the lungs, arrhythmias, and impairment in locomotor activities, mimicking some of the important symptoms of COVID-19. However, intranasal treatment with wtAIDS, but not mAIDS, peptide reduced fever, protected lungs, improved heart function, and enhanced locomotor activities in SARS-CoV-2 spike S1-intoxicated mice. Therefore, selective targeting of ACE2-to-SARS-CoV-2 interaction by wtAIDS may be beneficial for COVID-19. The online version contains supplementary material available at 10.1007/s11481-020-09979-8.
登录
查看更多内容
DOI:
10.1126/science.abc4730
发表时间:
2020-09-25
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Gu H;Chen Q;Yang G;He L;Fan H;Deng YQ;Wang Y;Teng Y;Zhao Z;Cui Y;Li Y;Li XF;Li J;Zhang NN;Yang X;Chen S;Guo Y;Zhao G;Wang X;Luo DY;Wang H;Yang X;Li Y;Han G;He Y;Zhou X;Geng S;Sheng X;Jiang S;Sun S;Qin CF;Zhou Y
通讯作者:
Zhou Y
影响因子:
4.4
作者:
Jana, Malabendu;Jana, Arundhati;Pahan, Kalipada
通讯作者:
Pahan, Kalipada
DOI:
10.1172/jci96209
发表时间:
2018-10-01
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
Rangasamy SB;Jana M;Roy A;Corbett GT;Kundu M;Chandra S;Mondal S;Dasarathi S;Mufson EJ;Mishra RK;Luan CH;Bennett DA;Pahan K
通讯作者:
Pahan K
DOI:
10.1038/nrmicro2801
发表时间:
2012-06-06
期刊:
Nature reviews. Microbiology
影响因子:
--
作者:
Edwards MR;Bartlett NW;Hussell T;Openshaw P;Johnston SL
通讯作者:
Johnston SL
DOI:
10.1038/nrmicro2090
发表时间:
2009-03
期刊:
Nature reviews. Microbiology
影响因子:
--
作者:
通讯作者:
--